BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz P, Smolnik R, Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. The Lancet 2019;394:1335-43. [DOI: 10.1016/s0140-6736(19)31872-0] [Cited by in Crossref: 243] [Cited by in F6Publishing: 77] [Article Influence: 81.0] [Reference Citation Analysis]
Number Citing Articles
1 Valgimigli M, Gragnano F. No free lunch-the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI. Ann Transl Med 2020;8:516. [PMID: 32395560 DOI: 10.21037/atm.2020.01.26] [Reference Citation Analysis]
2 Kuno T, Ueyama H, Takagi H, Ando T, Numasawa Y, Briasoulis A, Fox J, Bangalore S. Meta-analysis of Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Am J Cardiol 2020;125:521-7. [PMID: 31839147 DOI: 10.1016/j.amjcard.2019.11.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
3 Sotomi Y, Kozuma K, Kashiwabara K, Higuchi Y, Ando K, Morino Y, Ako J, Tanabe K, Muramatsu T, Nakazawa G, Hikoso S, Sakata Y; OPTIMA-AF Investigators. Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial. BMJ Open 2021;11:e048354. [PMID: 34907043 DOI: 10.1136/bmjopen-2020-048354] [Reference Citation Analysis]
4 Guo W, Chen X, Hao Y, Liu Q, Peng C, Zhao L, Feng Z, Wang X, Ruan H, Li L. Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: a meta-analysis. Aging (Albany NY) 2020;12:12930-42. [PMID: 32611835 DOI: 10.18632/aging.103359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Rafael Sádaba J, Tribouilloy C, Wojakowski W. Guía ESC/EACTS 2021 sobre el diagnóstico y tratamiento de las valvulopatías. Revista Española de Cardiología 2022. [DOI: 10.1016/j.recesp.2021.11.023] [Reference Citation Analysis]
6 Lyu SQ, Zhu J, Wang J, Wu S, Zhang H, Shao XH, Yang YM. Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention. Thromb Res 2021;209:16-22. [PMID: 34844044 DOI: 10.1016/j.thromres.2021.11.015] [Reference Citation Analysis]
7 Wang KL, Chiang CE. A Brave New World. Acta Cardiol Sin 2019;35:522-3. [PMID: 31571801 DOI: 10.6515/ACS.201909_35(5).20190906A] [Reference Citation Analysis]
8 Limbruno U, De Sensi F, Cresti A, Picchi A, Lena F, De Caterina R. Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome-Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant… Or, Rather, Temporary Dual Antiplatelet Therapy? J Clin Med 2020;9:E2673. [PMID: 32824861 DOI: 10.3390/jcm9082673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Masunaga N, Ogawa H, Minami K, Ishigami K, Ikeda S, Doi K, Hamatani Y, Yoshizawa T, Ide Y, Fujino A, Ishii M, Iguchi M, Wada H, Hasegawa K, Tsuji H, Esato M, Abe M, Akao M; Fushimi AF Registry Investigators. Association of Concomitant Coronary Artery Disease With Cardiovascular Events in Patients With Atrial Fibrillation - The Fushimi AF Registry. Circ J 2022. [PMID: 35786691 DOI: 10.1253/circj.CJ-22-0180] [Reference Citation Analysis]
10 Koziński M, Rejszel-Baranowska J, Młodawska E, Siller-Matula JM, Tomaszuk-Kazberuk A. Updated overview of evidence on optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutanous coronary intervention. Postepy Kardiol Interwencyjnej 2020;16:127-37. [PMID: 32636896 DOI: 10.5114/aic.2020.96055] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Bang OY, Kim S, On YK, Lee M, Jang S, Han S, Ryu J, Kang S, Suh HS, Kim Y. Comorbidities and Antithrombotic Treatment Pattern in Patients With Atrial Fibrillation. Front Neurol 2022;13:761603. [DOI: 10.3389/fneur.2022.761603] [Reference Citation Analysis]
12 Gremmel T, Huber K. Antithrombotic treatment strategies after PCI. Lancet 2020;395:865. [PMID: 32171403 DOI: 10.1016/S0140-6736(20)30028-3] [Reference Citation Analysis]
13 Lin M, Ye M, Ren J, Khalaf OI. Study on the Mechanism of Cardiac Intensive Care after Thoracoscopic Surgery. Computational and Mathematical Methods in Medicine 2022;2022:1-8. [DOI: 10.1155/2022/2894755] [Reference Citation Analysis]
14 Altoukhi RM, Alshouimi RA, Al Rammah SM, Alzahrani MY, Almutairi AR, Alshehri AM, Alfayez OM, Al Yami MS, Almohammed OA. Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: a systematic review and network meta-analysis. BMJ Open 2020;10:e036138. [PMID: 32994232 DOI: 10.1136/bmjopen-2019-036138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, Guo Y, Sriratanasathavorn C, Oh S, Okumura K, Lip GYH. 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. J Arrhythm 2021;37:1389-426. [PMID: 34887945 DOI: 10.1002/joa3.12652] [Reference Citation Analysis]
16 Harskamp RE, Fanaroff AC, Lopes RD, Wojdyla DM, Goodman SG, Thomas LE, Aronson R, Windecker S, Mehran R, Granger CB, Alexander JH. Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. Journal of the American College of Cardiology 2022;79:417-27. [DOI: 10.1016/j.jacc.2021.11.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
17 Goette A, Vranckx P. Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants. Eur Heart J Suppl 2020;22:I22-31. [PMID: 33088231 DOI: 10.1093/eurheart/suaa101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Cotoban AG, Udroiu CA, Vina R, Vinereanu D. Antithrombotic Strategies in Invasively Managed Patients with Non-ST Elevation Acute Coronary Syndromes and Non-Valvular Atrial Fibrillation in Romania. Maedica (Bucur) 2021;16:6-15. [PMID: 34221150 DOI: 10.26574/maedica.2020.16.1.6] [Reference Citation Analysis]
19 Chilbert MR, Reidy SE, Clark CM, Guszkowski M, Gargala E, Woodruff AE. Comparison of Bleeding Rates between Oral Anticoagulants in Combination with Dual Antiplatelet Therapy (Triple Therapy) in a Real-World Cohort. Hosp Pharm 2022;57:253-9. [DOI: 10.1177/00185787211024602] [Reference Citation Analysis]
20 Calderone D, Ingala S, Mauro MS, Angiolillo DJ, Capodanno D. Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events. Expert Rev Cardiovasc Ther 2021;:1-21. [PMID: 34915778 DOI: 10.1080/14779072.2021.2020100] [Reference Citation Analysis]
21 Al Said S, Ellscheid M, Beltsios ET, Frey N. Non-Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease. Hamostaseologie 2021. [PMID: 34662918 DOI: 10.1055/a-1606-7523] [Reference Citation Analysis]
22 Barnes GD. Combining antiplatelet and anticoagulant therapy in cardiovascular disease. Hematology Am Soc Hematol Educ Program 2020;2020:642-8. [PMID: 33275740 DOI: 10.1182/hematology.2020000151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Gargiulo G, Cannon CP, Gibson CM, Lopes RD, Vranckx P, Valgimigli M. The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events? Eur Heart J Cardiovasc Pharmacother 2021;7:e29-30. [PMID: 33340322 DOI: 10.1093/ehjcvp/pvaa141] [Reference Citation Analysis]
24 Luijkx J, Winkler P, van 't Hof A. Clopidogrel or ticagrelor alongside dabigatran in acute coronary syndrome and indication for NOAC: a study rationale. Future Cardiol 2021. [PMID: 34821510 DOI: 10.2217/fca-2021-0085] [Reference Citation Analysis]
25 Abdelnabi M, Benjanuwattra J, Okasha O, Almaghraby A, Saleh Y, Gerges F. Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! Egypt Heart J 2022;74:18. [PMID: 35347478 DOI: 10.1186/s43044-022-00259-9] [Reference Citation Analysis]
26 Mulder BA, Ten Berg J, Ten Cate H, van Es N, Hemels MEW, Kappelle LJ, Bearda Bakker HB, de Borst GJ, Drenth DJ, Geersing GJ, Rienstra M. Complex clinical scenarios with the use of direct oral anticoagulants in patients with atrial fibrillation: a multidisciplinary expert advisory board. Neth Heart J 2020;28:504-13. [PMID: 32394366 DOI: 10.1007/s12471-020-01424-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Choi EK. Cardiovascular Research Using the Korean National Health Information Database. Korean Circ J 2020;50:754-72. [PMID: 32725984 DOI: 10.4070/kcj.2020.0171] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
28 Zhao S, Hong X, Cai H, Liu M, Li B, Ma P. Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update. Front Cardiovasc Med 2021;8:660986. [PMID: 34262952 DOI: 10.3389/fcvm.2021.660986] [Reference Citation Analysis]
29 Jourdi G, Marquis-Gravel G, Martin AC, Lordkipanidzé M, Godier A, Gaussem P. Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines. Front Pharmacol 2022;13:878416. [PMID: 35571090 DOI: 10.3389/fphar.2022.878416] [Reference Citation Analysis]
30 Huisman MV. Antithrombotic treatment in atrial fibrillation patients needing percutaneous coronary intervention. Neth Heart J 2021;29:119-20. [PMID: 33566280 DOI: 10.1007/s12471-021-01546-x] [Reference Citation Analysis]
31 Kobayashi T, Sotomi Y, Hirata A, Sakata Y, Hirayama A, Higuchi Y. Impact of Direct Oral Anticoagulant Off-Label Reduced Dose in Combination With Antiplatelet Agents on Clinical Outcome - Propensity Score-Matching Analysis From the DIRECT Real-World Non-Valvular Atrial Fibrillation Registry. Circ Rep 2020;2:289-96. [PMID: 33693243 DOI: 10.1253/circrep.CR-20-0026] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
32 Grajek S, Kałużna-Oleksy M, Siller-Matula JM, Grajek M, Michalak M. Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Myocardial Infarction in Patients with Atrial Fibrillation with or without Percutaneous Coronary Interventions: A Meta-Analysis. J Pers Med 2021;11:1013. [PMID: 34683155 DOI: 10.3390/jpm11101013] [Reference Citation Analysis]
33 Vranckx P, Valgimigli M, Eckardt L, Gargiulo G, Goette A. Antithrombotic treatment strategies after PCI - Authors' reply. Lancet 2020;395:867-8. [PMID: 32171407 DOI: 10.1016/S0140-6736(20)30033-7] [Reference Citation Analysis]
34 Thomopoulos C, Ntalakouras J, Polyzos D, Konstantinidis D, Palaiodimou L, Tsivgoulis G, Tsioufis C. Net clinical benefit of a reduced dose of DOACs in non-valvular atrial fibrillation: A meta-analysis of randomized trials. Pharmacol Res 2021;:105902. [PMID: 34547386 DOI: 10.1016/j.phrs.2021.105902] [Reference Citation Analysis]
35 Wang W, Huang Q, Pan D, Zheng W, Zheng S. The optimal duration of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials. International Journal of Cardiology 2022. [DOI: 10.1016/j.ijcard.2022.03.047] [Reference Citation Analysis]
36 Han S, Han S, Jang SW, Lee MY, On YK, Bang OY, Lee JM, Park YJ, Shin JS, Kang S, Suh HS, Kim YH. Treatment Pattern of Antithrombotic Therapy over Time after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation in Real-World Practice in Korea. Healthcare (Basel) 2021;9:1185. [PMID: 34574959 DOI: 10.3390/healthcare9091185] [Reference Citation Analysis]
37 Lucà F, Parrini I, Abrignani MG, Rao CM, Piccioni L, Di Fusco SA, Ceravolo R, Bisceglia I, Riccio C, Gelsomino S, Colivicchi F, Gulizia MM. Management of Acute Coronary Syndrome in Cancer Patients: It's High Time We Dealt with It. J Clin Med 2022;11:1792. [PMID: 35407399 DOI: 10.3390/jcm11071792] [Reference Citation Analysis]
38 Gencer B, Eisen A, Berger D, Nordio F, Murphy SA, Grip LT, Chen C, Lanz H, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. Am Heart J 2022;247:24-32. [PMID: 34990581 DOI: 10.1016/j.ahj.2021.12.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Pradhan A, Bhandari M, Vishwakarma P, Sethi R. Novel Dual Therapy: A Paradigm Shift in Anticoagulation in Patients of Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. TH Open 2020;4:e332-43. [PMID: 33163856 DOI: 10.1055/s-0040-1719081] [Reference Citation Analysis]
40 Zhao S, Hong X, Cao J, Cai H, Du S, Ma P. Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration. Front Pharmacol 2020;11:1293. [PMID: 32973522 DOI: 10.3389/fphar.2020.01293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Coner A, Ekmekci C, Aydin G, Kilavuz Dogan Y, Arican Ozluk O, Kilic S, Celik Y, Ungan I, Begenc Tascanov M, Duz R, Polat V, Ozkan H, Ozyasar M, Tuluce K, Icli A, Kurt D, Cetin N, Gul M, Inci S, Zoghi M, Ergene O, Onsel Turk U. Demographic, Clinical, and Angiographic Characteristics of Atrial Fibrillation Patients Suffering From de novo Acute Myocardial Infarction: A Subgroup Analysis of the MINOCA-TR Study Population. J Atr Fibrillation 2021;13:20200468. [PMID: 34950351 DOI: 10.4022/jafib.20200468] [Reference Citation Analysis]
42 Kim Y, Johnson TW, Jeong YH. To drop or not to drop the antiplatelet agent, that is the question for patients with atrial fibrillation and chronic coronary syndrome undergoing percutaneous coronary intervention. Cardiol J 2020;27:1-3. [PMID: 32103476 DOI: 10.5603/CJ.2020.0012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Kozieł M, Potpara TS, Lip GYH. Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting. Res Pract Thromb Haemost 2020;4:357-65. [PMID: 32211570 DOI: 10.1002/rth2.12319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA; Writing Committee Members. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021:S0735-1097(21)06158-1. [PMID: 34895950 DOI: 10.1016/j.jacc.2021.09.006] [Cited by in Crossref: 80] [Cited by in F6Publishing: 51] [Article Influence: 80.0] [Reference Citation Analysis]
45 Shah R, Labroo A, Davis DA, Le FK. Increased risk of stent thrombosis with use of a direct oral anticoagulant and a single antiplatelet agent after PCI: A meta-analysis. Catheter Cardiovasc Interv 2021;98:E490-2. [PMID: 32845076 DOI: 10.1002/ccd.29205] [Reference Citation Analysis]
46 Wiebe J, Ndrepepa G, Kufner S, Lahmann AL, Xhepa E, Kuna C, Voll F, Gosetti R, Laugwitz KL, Joner M, Kastrati A, Cassese S. Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2021;10:e018304. [PMID: 33410332 DOI: 10.1161/JAHA.120.018304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Botto G, Ameri P, Cappellari M, Dentali F, Ferri N, Parrini I, Porto I, Squizzato A, Camporese G. Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation. Adv Ther 2021;38:2891-907. [PMID: 34019247 DOI: 10.1007/s12325-021-01769-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Beaulieu MC, Boivin-Proulx LA, Matteau A, Mansour S, Gobeil JF, Potter BJ. Evolution of Antithrombotic Management of Atrial Fibrillation After Percutaneous Coronary Intervention Over 10 Years and Guidelines Uptake. CJC Open 2021;3:1025-32. [PMID: 34505042 DOI: 10.1016/j.cjco.2021.04.002] [Reference Citation Analysis]
49 Bikdeli B, Zahedi Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. JAMA Cardiol 2022. [PMID: 35648414 DOI: 10.1001/jamacardio.2022.1292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
50 Thiele H, Jobs A. [ESC guidelines 2020: acute coronary syndrome without persistent ST-segment elevation : What is new?]. Herz 2021;46:3-13. [PMID: 33236199 DOI: 10.1007/s00059-020-05002-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 van der Pals J, Holmqvist F, Borgquist R, Götberg M, Nseir M, Koul S, Isma N, Scherstén F, Tydén P, Braun OÖ, Erlinge D. Characteristics and outcomes in patients with atrial fibrillation and acute coronary syndrome treated with ticagrelor and novel oral anticoagulants. Thrombosis Update 2021;3:100054. [DOI: 10.1016/j.tru.2021.100054] [Reference Citation Analysis]
52 Vranckx P, Valgimigli M. Antithrombotic therapy in patients with atrial fibrillation undergoing PCI remains a moving target, yet with a clearer direction! EuroIntervention 2022;18:e267-8. [PMID: 35866255 DOI: 10.4244/EIJ-E-22-00004] [Reference Citation Analysis]
53 Lee CC, Chang CH, Hung Y, Lin CS, Yang SP, Cheng SM, Yu FH, Lin WS, Lin WY. Changes of antithrombotic prescription in atrial fibrillation patients with acute coronary syndrome or percutaneous coronary intervention and the subsequent impact on long-term outcomes: a longitudinal cohort study. Thromb J 2021;19:100. [PMID: 34906162 DOI: 10.1186/s12959-021-00353-z] [Reference Citation Analysis]
54 Fernández-Ruiz I. Edoxaban noninferior to VKA in AF after PCI. Nat Rev Cardiol 2019;16:646. [PMID: 31511658 DOI: 10.1038/s41569-019-0272-4] [Reference Citation Analysis]
55 Benetou DR, Varlamos C, Mpahara A, Alexopoulos D. Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Am J Cardiovasc Drugs 2021;21:11-20. [PMID: 32170515 DOI: 10.1007/s40256-020-00403-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
56 Sorbets E, Steg PG. Direct-acting Anticoagulants in Chronic Coronary Syndromes. Eur Cardiol 2020;15:1-7. [PMID: 32180831 DOI: 10.15420/ecr.2018.24.2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Guedeney P, Mesnier J, Sorrentino S, Abcha F, Zeitouni M, Lattuca B, Silvain J, De Rosa S, Indolfi C, Collet JP, Kerneis M, Montalescot G. Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med 2020;9:E680. [PMID: 32138287 DOI: 10.3390/jcm9030680] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
58 Torii S, Yamamoto T, Nakamura N, Ijichi T, Yoshikawa A, Ito Y, Sugidachi A, Ikari Y, Nakazawa G. Antiplatelet Effect of Single Antiplatelet Therapy With Prasugrel and Oral Anticoagulation After Stent Implantation in a Rabbit Arteriovenous Shunt Model. Circ Rep 2021;3:504-10. [PMID: 34568629 DOI: 10.1253/circrep.CR-21-0084] [Reference Citation Analysis]
59 Leening MJG, Mahmoud KD. Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology. Eur J Epidemiol 2021;36:1103-9. [PMID: 34792692 DOI: 10.1007/s10654-021-00820-x] [Reference Citation Analysis]
60 Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, Guo Y, Sriratanasathavorn C, Oh S, Okumura K, Lip GYH. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thromb Haemost 2021. [PMID: 34773920 DOI: 10.1055/s-0041-1739411] [Reference Citation Analysis]
61 Schukraft S, Huwyler T, Ottiger-Mankaka C, Lehmann S, Cook E, Doomun D, Doomun I, Goy JJ, Stauffer JC, Togni M, Arroyo D, Puricel S, Cook S. Bleeding Risk Profile in Patients on Oral Anticoagulation Undergoing Percutaneous Coronary Interventions: A Prospective 24 Months Cohort Study. Front Cardiovasc Med 2021;8:589426. [PMID: 34660705 DOI: 10.3389/fcvm.2021.589426] [Reference Citation Analysis]
62 Lemesle G, Bauters C, Bonello L, Fauchier L, Cayla G, Marijon E, Guenoun M, Schurtz G, Ninni S, Richardson M, Albert F, Cohen S, Lamblin N, Danchin N. Management of antithrombotics in situations with a gap in evidence: A national French survey focusing on patients with coronary artery disease and atrial fibrillation. Int J Cardiol 2021:S0167-5273(21)01966-5. [PMID: 34864080 DOI: 10.1016/j.ijcard.2021.11.077] [Reference Citation Analysis]
63 De Caterina R, Agewall S, Andreotti F, Angiolillo DJ, Bhatt DL, Byrne RA, Collet JP, Eikelboom J, Fanaroff AC, Gibson CM, Goette A, Hindricks G, Lip GYH, Potpara T, Thiele H, Lopes RD, Galli M. Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. Eur Heart J 2022:ehac294. [PMID: 35925556 DOI: 10.1093/eurheartj/ehac294] [Reference Citation Analysis]
64 Caracciolo A, Mazzone P, Laterra G, Garcia-Ruiz V, Polimeni A, Galasso S, Saporito F, Carerj S, D'Ascenzo F, Marquis-Gravel G, Giustino G, Costa F. Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions. J Clin Med 2019;8:E2016. [PMID: 31752292 DOI: 10.3390/jcm8112016] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Boivin-Proulx LA, Deneault-Marchand A, Matteau A, Mansour S, Gobeil F, Camm JA, Fox KAA, Potter BJ. Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. Clin Cardiol 2020;43:216-21. [PMID: 31850592 DOI: 10.1002/clc.23316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
66 Capodanno D, Baber U, Bhatt DL, Collet JP, Dangas G, Franchi F, Gibson CM, Gwon HC, Kastrati A, Kimura T, Lemos PA, Lopes RD, Mehran R, O'Donoghue ML, Rao SV, Rollini F, Serruys PW, Steg PG, Storey RF, Valgimigli M, Vranckx P, Watanabe H, Windecker S, Angiolillo DJ. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nat Rev Cardiol 2022. [PMID: 35697777 DOI: 10.1038/s41569-022-00725-6] [Reference Citation Analysis]
67 Capodanno D, Di Maio M, Greco A, Bhatt DL, Gibson CM, Goette A, Lopes RD, Mehran R, Vranckx P, Angiolillo DJ. Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2020;9:e017212. [PMID: 32805186 DOI: 10.1161/JAHA.120.017212] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
68 Romiti GF, Basili S, Proietti M. Antithrombotic treatment strategies after PCI. Lancet 2020;395:866. [PMID: 32171405 DOI: 10.1016/S0140-6736(20)30031-3] [Reference Citation Analysis]
69 Chua SK, Chen LC, Shyu KG, Cheng JJ, Hung HF, Chiu CZ, Lin CM. Antithrombotic Strategies in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention: A Systemic Review and Network Meta-Analysis of Randomized Controlled Trials. J Clin Med 2020;9:E1062. [PMID: 32276535 DOI: 10.3390/jcm9041062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C, Wojakowski W; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 2021;60:727-800. [PMID: 34453161 DOI: 10.1093/ejcts/ezab389] [Cited by in Crossref: 15] [Article Influence: 15.0] [Reference Citation Analysis]
71 Camarero TG, de la Torre Hernández JM. Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy. Eur Cardiol 2020;15:1-8. [PMID: 32180829 DOI: 10.15420/ecr.2019.25.2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Patel A, Goodman SG, Tan M, Suskin N, McKelvie R, Mathew AL, Lutchmedial S, Dehghani P, Lavoie AJ, Huynh T, Lavi S, Philipp R, Khan R, Yan AT, Radhakrishnan S, Sedlak T, Brunner N, Kim HH, Cieza T, Kassam S, Fordyce CB, Heffernan M, Jedrzkiewicz S, Madan M, Ahmed S, Barry C, Dery JP, Bagai A; Canadian ACS Reflective II Investigators. Contemporary use of guideline-based higher potency P2Y12 receptor inhibitor therapy in patients with moderate-to-high risk non-ST-segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross-sectional study. Clin Cardiol 2021;44:839-47. [PMID: 33982795 DOI: 10.1002/clc.23618] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Goette A, Eckardt L, Valgimigli M, Lewalter T, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Tijssen JG, Vranckx P. Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis. Clin Res Cardiol 2021;110:831-40. [PMID: 33098470 DOI: 10.1007/s00392-020-01760-4] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
74 Lu W, Wang Y, Chen L, Li Y, Zhang R, Chen Z, Yan J, Yang M, Han B, Wang Z, He S, Chen L, Wu X, Zeng H, Ma L, Shi G, Yin J, Chen J, Ma G. Antithrombotic Therapy With Ticagrelor in Atrial Fibrillation Subjects After Percutaneous Coronary Intervention. Front Cardiovasc Med 2021;8:745549. [PMID: 34712714 DOI: 10.3389/fcvm.2021.745549] [Reference Citation Analysis]
75 Park J, Choi EK, Han KD, Kim B, Choi YJ, Lee SR, Kang J, Cha MJ, Park KW, Oh S, Lip GYH. Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention. PLoS One 2020;15:e0240161. [PMID: 33057407 DOI: 10.1371/journal.pone.0240161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Natsuaki M, Sonoda S, Yoshioka G, Hongo H, Kaneko T, Kashiyama K, Yokoi K, Hikichi Y, Node K. Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives. Cardiovasc Interv Ther 2022. [PMID: 35237927 DOI: 10.1007/s12928-022-00847-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Park J, Jung JH, Choi EK, Lee SW, Kwon S, Lee SR, Kang J, Han KD, Park KW, Oh S, Lip GYH. Longitudinal Patterns in Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention in the Non-Vitamin K Oral Anticoagulant Era: A Nationwide Population-Based Study. J Clin Med 2021;10:1505. [PMID: 33916604 DOI: 10.3390/jcm10071505] [Reference Citation Analysis]
78 Bahit MC, Vora AN, Li Z, Wojdyla DM, Thomas L, Goodman SG, Aronson R, Jordan JD, Kolls BJ, Dombrowski KE, Vinereanu D, Halvorsen S, Berwanger O, Windecker S, Mehran R, Granger CB, Alexander JH, Lopes RD. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. JAMA Cardiol 2022. [PMID: 35612866 DOI: 10.1001/jamacardio.2022.1166] [Reference Citation Analysis]
79 Madsen JM, Jacobsen MR, Sabbah M, Topal DG, Jabbari R, Glinge C, Køber L, Torp-Pedersen C, Pedersen F, Sørensen R, Holmvang L, Engstrøm T, Lønborg JT. Long-term prognostic outcomes and implication of oral anticoagulants in patients with new-onset atrial fibrillation following st-segment elevation myocardial infarction. Am Heart J 2021;238:89-99. [PMID: 33957102 DOI: 10.1016/j.ahj.2021.04.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
80 De Rosa S, Sabatino J, Polimeni A, Sorrentino S, Indolfi C. Dual anti-thrombotic treatment with direct anticoagulants improves clinical outcomes in patients with Atrial Fibrillation with ACS or undergoing PCI. A systematic review and meta-analysis. PLoS One 2020;15:e0235511. [PMID: 32645042 DOI: 10.1371/journal.pone.0235511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
81 Capodanno D, Bhatt DL, Gibson CM, James S, Kimura T, Mehran R, Rao SV, Steg PG, Urban P, Valgimigli M, Windecker S, Angiolillo DJ. Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol 2021. [PMID: 34426673 DOI: 10.1038/s41569-021-00598-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Dharma S. Double Antithrombotic versus Triple Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. Int J Angiol 2020;29:81-7. [PMID: 32476809 DOI: 10.1055/s-0040-1702208] [Reference Citation Analysis]
83 Gargiulo G, Cannon CP, Gibson CM, Goette A, Lopes RD, Oldgren J, Korjian S, Windecker S, Esposito G, Vranckx P, Valgimigli M. Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J Cardiovasc Pharmacother 2021;7:f50-60. [PMID: 33119069 DOI: 10.1093/ehjcvp/pvaa116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
84 Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger CB, Verheugt FWA, Li J, Ten Berg JM, Sarafoff N, Vranckx P, Goette A, Gibson CM, Alexander JH. Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. JAMA Cardiol 2020;5:582-9. [PMID: 32101251 DOI: 10.1001/jamacardio.2019.6175] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 27.0] [Reference Citation Analysis]
85 Choxi R, Kapoor K, Mackman N, Jovin IS. Direct Oral Anticoagulants and Coronary Artery Disease. Arterioscler Thromb Vasc Biol 2022;42:553-64. [PMID: 35296151 DOI: 10.1161/ATVBAHA.121.317171] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Mori H, Fukui K, Maeda A, Akashi Y, Ako J, Ikari Y, Ebina T, Tamura K, Namiki A, Michishita I, Kimura K, Suzuki H. Impact of atrial fibrillation and the clinical outcomes in patients with acute myocardial infarction from the K-ACTIVE registry. J Cardiol 2022:S0914-5087(22)00029-6. [PMID: 35216889 DOI: 10.1016/j.jjcc.2022.02.007] [Reference Citation Analysis]
87 Sokol J, Nehaj F, Ivankova J, Mokan M, Lisa L, Zolkova J, Vadelova L, Mokan M, Stasko J. Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation. Clin Appl Thromb Hemost 2020;26:1076029620948585. [PMID: 33054412 DOI: 10.1177/1076029620948585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Watson RA, Johnson DM, Dharia RN, Merli GJ, Doherty JU. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hosp Pract (1995) 2020;48:169-79. [PMID: 32429774 DOI: 10.1080/21548331.2020.1772639] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
89 Kuno T, Ueyama H, Takagi H, Bangalore S. The risk of stent thrombosis of dual antithrombotic therapy for patients who require oral anticoagulant undergoing percutaneous coronary intervention: insights of a meta-analysis of randomized trials. Scand Cardiovasc J 2022;:1-3. [PMID: 35001785 DOI: 10.1080/14017431.2021.2025264] [Reference Citation Analysis]
90 Auer J, Berent R, Gurtner F. Antithrombotic treatment strategies after PCI. Lancet 2020;395:865-6. [PMID: 32171404 DOI: 10.1016/S0140-6736(20)30032-5] [Reference Citation Analysis]
91 Vranckx P, Angiolillo DJ, Valgimigli M. Patients With Atrial Fibrillation and PCI or ACS. Journal of the American College of Cardiology 2022;79:428-31. [DOI: 10.1016/j.jacc.2021.11.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Schäfer A, Flierl U, Berliner D, Bauersachs J. Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients. Cardiovasc Drugs Ther 2020;34:555-68. [PMID: 32350792 DOI: 10.1007/s10557-020-06981-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
93 Verdoia M, Camaro C, Kedhi E, Marcolongo M, Suryapranata H, De Luca G. Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues. Cardiovasc Ther 2020;2020:6495036. [PMID: 32328172 DOI: 10.1155/2020/6495036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Wang S, Liu Y, Wang L, Zuo H, Tian Y, Wang Y, Yin D, Zhang H, Tian Y. Optimisation of oral anticoagulants for patients with atrial fibrillation within 12 months after percutaneous coronary intervention: A meta-analysis and systematic review. Int J Cardiol Heart Vasc 2021;36:100850. [PMID: 34401468 DOI: 10.1016/j.ijcha.2021.100850] [Reference Citation Analysis]
95 Alkindi FA, Rafie IM. Anticoagulation in Patients with Atrial Fibrillation and Coronary Artery Disease. Heart Views 2020;21:32-6. [PMID: 32082498 DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_138_19] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 De Luca L, Mistrulli R, Veneziano FA, Grigioni F, Volpe M, Musumeci F, Gabrielli D. Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. J Clin Med 2022;11:512. [PMID: 35159964 DOI: 10.3390/jcm11030512] [Reference Citation Analysis]
97 Gimbel ME, Tavenier AH, Bor W, Hermanides RS, de Vrey E, Heestermans T, Gin MTJ, Waalewijn R, Hofma S, den Hartog F, Jukema W, von Birgelen C, Voskuil M, Kelder J, Deneer V, Ten Berg JM. Ticagrelor Versus Clopidogrel in Older Patients with NSTE-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial. J Clin Med 2020;9:E3249. [PMID: 33053622 DOI: 10.3390/jcm9103249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Iqbal H, Straw S, Craven TP, Stirling K, Wheatcroft SB, Witte KK. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. ESC Heart Fail 2020;7:2032-41. [PMID: 32583975 DOI: 10.1002/ehf2.12718] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
99 Colonna P, von Heymann C, Santamaria A, Saxena M, Vanassche T, Wolpert D, Laeis P, Wilkins R, Chen C, Unverdorben M. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study. Clin Cardiol 2020;43:769-80. [PMID: 32406557 DOI: 10.1002/clc.23379] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
100 Casula M, Fortuni F, Ferlini M, Fabris F, Oltrona Visconti L, Leonardi S. Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Am J Cardiovasc Drugs 2021;21:231-40. [PMID: 32895853 DOI: 10.1007/s40256-020-00436-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
101 Liedtke JP, Ahrens I. [Antiplatelet therapy and anticoagulation in patients with coronary heart disease]. Dtsch Med Wochenschr 2021;146:1041-50. [PMID: 34416771 DOI: 10.1055/a-1241-6676] [Reference Citation Analysis]
102 Khan SU, Osman M, Khan MU, Khan MS, Zhao D, Mamas MA, Savji N, Al-Abdouh A, Hasan RK, Michos ED. Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. Ann Intern Med 2020;172:474-83. [PMID: 32176890 DOI: 10.7326/M19-3763] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 7.5] [Reference Citation Analysis]
103 Gargiulo G, Goette A, Vranckx P, Valgimigli M. Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help. Eur Heart J 2020;41:1701-2. [PMID: 32060541 DOI: 10.1093/eurheartj/ehaa076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
104 De Luca L, Rubboli A, Lettino M, Tubaro M, Leonardi S, Casella G, Valente S, Rossini R, Sciahbasi A, Natale E, Trambaiolo P, Navazio A, Cipriani M, Corda M, De Nardo A, Francese GM, Napoletano C, Tizzani E, Nardi F, Roncon L, Caldarola P, Riccio C, Gabrielli D, Oliva F, Massimo Gulizia M, Colivicchi F. ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes. Eur Heart J Suppl 2022;24:C254-71. [PMID: 35663586 DOI: 10.1093/eurheartj/suac020] [Reference Citation Analysis]
105 Camaj A, Fuster V, Giustino G, Bienstock SW, Sternheim D, Mehran R, Dangas GD, Kini A, Sharma SK, Halperin J, Dweck MR, Goldman ME. Left Ventricular Thrombus Following Acute Myocardial Infarction: JACC State-of-the-Art Review. J Am Coll Cardiol 2022;79:1010-22. [PMID: 35272796 DOI: 10.1016/j.jacc.2022.01.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
106 Noubiap JJ, Agbaedeng TA, Nyaga UF, Lau DH, Worthley MI, Nicholls SJ, Sanders P. Atrial fibrillation incidence, prevalence, predictors, and adverse outcomes in acute coronary syndromes: A pooled analysis of data from 8 million patients. J Cardiovasc Electrophysiol 2022. [PMID: 34981859 DOI: 10.1111/jce.15351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Triska J, Haddadin F, Madanat L, Jabri A, Daher M, Birnbaum Y, Jneid H. The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Cardiovasc Drugs Ther 2022. [PMID: 35829979 DOI: 10.1007/s10557-022-07367-3] [Reference Citation Analysis]
108 Towashiraporn K, Krittayaphong R. Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome. IJGM 2022;Volume 15:2397-414. [DOI: 10.2147/ijgm.s289295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Tonko JB, Wright MJ. Review of the 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation-What Has Changed and How Does This Affect Daily Practice. J Clin Med 2021;10:3922. [PMID: 34501370 DOI: 10.3390/jcm10173922] [Reference Citation Analysis]
110 Guedeney P, Collet JP. Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines. J Clin Med 2020;9:E3474. [PMID: 33126578 DOI: 10.3390/jcm9113474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
111 Sullivan AE, Nanna MG, Rao SV, Cantrell S, Gibson CM, Verheugt FWA, Peterson ED, Lopes RD, Alexander JH, Granger CB, Yee MK, Kong DF. A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 2020;96:E102-9. [PMID: 31713326 DOI: 10.1002/ccd.28535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
112 Rowland B, Batty JA, Mehran R, Kunadian V. Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants after Percutaneous Coronary Intervention. In: Dangas GD, Di Mario C, Thiele H, Barlis P, Addo T, Claessen B, Hengstenberg C, Kipshidze N, editors. Interventional Cardiology. Wiley; 2022. pp. 453-64. [DOI: 10.1002/9781119697367.ch42] [Reference Citation Analysis]
113 Numasawa Y, Sawano M, Fukuoka R, Ejiri K, Kuno T, Shoji S, Kohsaka S. Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia. J Clin Med 2020;9:E1963. [PMID: 32585929 DOI: 10.3390/jcm9061963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
114 Rivolo S, Di Fusco M, Polanco C, Kang A, Dhanda D, Savone M, Skandamis A, Kongnakorn T, Soto J. Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain. PLoS One 2021;16:e0259251. [PMID: 34767564 DOI: 10.1371/journal.pone.0259251] [Reference Citation Analysis]
115 Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-lundqvist C, Boriani G, Castella M, Dan G, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, Meir ML, Lane DA, Lebeau J, Lettino M, Lip GY, Pinto FJ, Neil Thomas G, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL. Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS). Revista Española de Cardiología 2021;74:437.e1-437.e116. [DOI: 10.1016/j.recesp.2020.10.022] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
116 Buccheri S, Angiolillo DJ, Capodanno D. Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. Ther Adv Cardiovasc Dis 2019;13:1753944719891688. [PMID: 31814532 DOI: 10.1177/1753944719891688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
117 Breuckmann F, Settelmeier S, Rassaf T, Post F, Haerer W, Bauersachs J, Mudra H, Voigtländer T, Senges J, Münzel T, Giannitsis E. Survey of clinical practice pattern in Germany's certified chest pain units : Adherence to the European Society of Cardiology guidelines on non-ST-segment elevation acute coronary syndrome. Herz 2021. [PMID: 34755215 DOI: 10.1007/s00059-021-05079-2] [Reference Citation Analysis]
118 Yoh K, Nishikawa H, Enomoto H, Iwata Y, Ikeda N, Aizawa N, Nishimura T, Iijima H, Nishiguchi S. Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases. Diagnostics (Basel) 2020;10:E238. [PMID: 32325995 DOI: 10.3390/diagnostics10040238] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
119 Bhogal S, Alkhouli M, White CJ, Bailey S, Mamas M, Haddad E, Paul TK. Is There a Role for Triple Therapy After ACS? Curr Cardiol Rep 2022. [PMID: 35112242 DOI: 10.1007/s11886-022-01634-3] [Reference Citation Analysis]
120 Stepanović-petrović R, Nastić K. Direct oral anticoagulants: A new chapter in anticoagulation therapy. Arhiv za farmaciju 2020;70:249-68. [DOI: 10.5937/arhfarm2005249s] [Reference Citation Analysis]
121 Menditto A, Antonicelli R. Is dual therapy the correct strategy in frail elderly patients with atrial fibrillation and acute coronary syndrome? J Geriatr Cardiol 2020;17:51-7. [PMID: 32133036 DOI: 10.11909/j.issn.1671-5411.2020.01.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Riddle M, McCallum R, Ojha CP, Paul TK, Gupta V, Baran DA, Prakash BV, Misra A, Mares AC, Abedin M, Kedar A, Mulukutla V, Ibrahim A, Nagarajarao H. Advances in the management of atrial fibrillation with a special focus on non-pharmacological approaches to prevent thromboembolism: a review of current recommendations. J Investig Med 2020;68:1317-33. [PMID: 33203786 DOI: 10.1136/jim-2020-001500] [Reference Citation Analysis]
123 de Groot JR. Stroke prevention in patients with atrial fibrillation and comorbidities: evidence and common sense. Neth Heart J 2020;28:501-3. [PMID: 32897488 DOI: 10.1007/s12471-020-01491-1] [Reference Citation Analysis]
124 Lyu SQ, Zhu J, Wang J, Wu S, Zhang H, Shao XH, Yang YM. Predictive performance of different bleeding risk scores in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention. Platelets 2022;:1-11. [PMID: 35103582 DOI: 10.1080/09537104.2021.2007870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Kwon S, Jung JH, Choi EK, Lee SW, Park J, Lee SR, Kang J, Han K, Park KW, Oh S, Lip GYH. Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Korean Circ J 2021;51:409-22. [PMID: 33764010 DOI: 10.4070/kcj.2020.0407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Mughal LH, Sastry S. Advances in the treatment of ST Elevation Myocardial Infarction in the UK. JRSM Cardiovascular Disease 2022;11:204800402210755. [DOI: 10.1177/20480040221075519] [Reference Citation Analysis]
127 Su MI, Cheng YC, Huang YC, Liu CW. The Impact of Atrial Fibrillation on One-Year Mortality in Patients with Severe Lower Extremity Arterial Disease. J Clin Med 2022;11:1936. [PMID: 35407544 DOI: 10.3390/jcm11071936] [Reference Citation Analysis]
128 De Luca L, Rubboli A, Bolognese L, Gonzini L, Urbinati S, Murrone A, Scotto di Uccio F, Ferrari F, Lucà F, Caldarola P, Lucci D, Gabrielli D, Di Lenarda A, Gulizia MM; MATADOR-PCI Investigators. Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study. BMJ Open 2020;10:e041044. [PMID: 33371033 DOI: 10.1136/bmjopen-2020-041044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
129 Bor WL, de Veer AJW, Olie RH, Rikken SAOF, Chan Pin Yin DRPP, Herrman JPR, Vrolix M, Meuwissen M, Vandendriessche T, van Mieghem C, Magro M, Bennaghmouch N, Hermanides R, Adriaenssens T, Dewilde WJM, Ten Berg JM. Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study. EuroIntervention 2022;18:e303-13. [PMID: 35370126 DOI: 10.4244/EIJ-D-21-00703] [Reference Citation Analysis]
130 Smits PC, Frigoli E, Tijssen J, Jüni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, Iñiguez A, Schultz C, Kornowski R, Ong PJL, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Heg D, Valgimigli M; MASTER DAPT Investigators. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. Circulation 2021;144:1196-211. [PMID: 34455849 DOI: 10.1161/CIRCULATIONAHA.121.056680] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
131 Linden K, Mailey J, Kearney A, Menown IBA. Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials. Adv Ther 2020;37:2620-45. [PMID: 32361851 DOI: 10.1007/s12325-020-01355-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Benetou D, Vlachakis PK, Varlamos C, Alexopoulos D. Antithrombotic Therapy in Complex Percutaneous Coronary Intervention Patients Requiring Chronic Anticoagulation. US Cardiology Review 2021;15:e09. [DOI: 10.15420/usc.2020.31] [Reference Citation Analysis]
133 Williams M, Ahuja T, Raco V, Papadopoulos J, Green D, Yuriditsky E, Arnouk S. Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients. J Thromb Thrombolysis 2022. [PMID: 35381944 DOI: 10.1007/s11239-022-02641-5] [Reference Citation Analysis]
134 Gjermeni D, Vetter H, Szabó S, Anfang V, Leggewie S, Hesselbarth D, Duerschmied D, Trenk D, Olivier CB. Thrombelastography Compared with Multiple Impedance Aggregometry to Assess High On-Clopidogrel Reactivity in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. JCM 2022;11:4237. [DOI: 10.3390/jcm11144237] [Reference Citation Analysis]
135 Pazan F, Collins R, Gil VM, Hanon O, Hardt R, Hoffmeister M, Monteiro P, Quinn TJ, Ropers D, Sergi G, Verheugt FWA, Wehling M. A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019). Drugs Aging 2020;37:539-48. [PMID: 32500503 DOI: 10.1007/s40266-020-00771-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
136 Cho MS, Kang DY, Oh YS, Lee CH, Choi EK, Lee JH, Kwon CH, Park GM, Park HW, Park KH, Park KM, Hwang J, Yoo KD, Cho YR, Kim YR, Hwang KW, Jin ES, Kim PJ, Kim KH, Park DW, Nam GB. Edoxaban-based long-term antithrombotic therapy in patients with atrial fibrillation and stable coronary disease: Rationale and design of the randomized EPIC-CAD trial. Am Heart J 2022;247:123-31. [PMID: 35149036 DOI: 10.1016/j.ahj.2022.01.014] [Reference Citation Analysis]
137 Lv WH, Dong JZ, Du X, Hu R, He L, Long DY, Sang CH, Jia CQ, Feng L, Li X, Ning M, Chen X, Cui YK, Tang RB, Ma CS. Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome. J Thromb Thrombolysis 2021. [PMID: 34677727 DOI: 10.1007/s11239-021-02588-z] [Reference Citation Analysis]
138 Vranckx P, Valgimigli M, Eckardt L, Lewalter T, Unikas R, Marin F, Schiele F, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Tijssen J, Goette A. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. Eur Heart J 2020;41:4497-504. [PMID: 32860041 DOI: 10.1093/eurheartj/ehaa617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
139 Leblanc K, Macgillivray J, Carroccia A, Macle L, Andrade JG. The 2020 CCS atrial fibrillation guidelines for pharmacists: Top 10 takeaways. Can Pharm J 2022;155:107-18. [DOI: 10.1177/17151635211058160] [Reference Citation Analysis]
140 Bergmark BA, Mathenge N, Merlini PA, Lawrence-wright MB, Giugliano RP. Acute coronary syndromes. The Lancet 2022;399:1347-58. [DOI: 10.1016/s0140-6736(21)02391-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
141 Suo N, Yang Y, Wang J, Zhang H, Shao X, Wu S, Zhu J. Evolving Antithrombotic Treatment Patterns for Patients With Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome or Underwent Percutaneous Coronary Intervention in China: A Cross-Sectional Study. Front Cardiovasc Med 2022;9:846803. [DOI: 10.3389/fcvm.2022.846803] [Reference Citation Analysis]
142 Ikushima I, Akasaka T, Morishima Y, Takita A, Motohashi T, Kimura T. Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study. Thromb J 2020;18:10. [PMID: 32536828 DOI: 10.1186/s12959-020-00223-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Warkentin L, Hueber S, Deiters B, Klohn F, Kühlein T. Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data. Thromb J 2022;20:31. [PMID: 35619140 DOI: 10.1186/s12959-022-00389-9] [Reference Citation Analysis]
144 Panov AV. Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Racionalʹnaâ farmakoterapiâ v kardiologii 2021;17:628-37. [DOI: 10.20996/1819-6446-2021-07-02] [Reference Citation Analysis]
145 Lee JH, Kim SH, Lee W, Cho Y, Kang SH, Park JJ, Oh IY, Yoon CH, Suh JW, Cho YS, Youn TJ, Chae IH, Choi DJ. New-onset paroxysmal atrial fibrillation in acute myocardial infarction: increased risk of stroke. BMJ Open 2020;10:e039600. [PMID: 32967885 DOI: 10.1136/bmjopen-2020-039600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
146 Riesinger L, Strobl C, Leistner DM, Gori T, Akin I, Mehr M, Kellnar A, Mahabadi AA, Bogossian H, Block M, Edelmann F, Sarafoff N, Sibbing D, Ince H, Rassaf T, Mansmann U, Mehilli J, Kääb S, Hausleiter J, Massberg S, Wakili R. Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting. Int J Cardiol Heart Vasc 2021;35:100810. [PMID: 34258380 DOI: 10.1016/j.ijcha.2021.100810] [Reference Citation Analysis]
147 Galli M, Andreotti F, D'Amario D, Vergallo R, Montone RA, Niccoli G, Crea F. Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. Int J Cardiol Heart Vasc 2020;28:100524. [PMID: 32435688 DOI: 10.1016/j.ijcha.2020.100524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
148 Pezzella FR, Mangiardi M, Ferrante M, Fabiano S, Anticoli S, Pennacchi FG, Urso A, De Luca L, Caso V. Management of Oral Anticoagulation and Antiplatelet Therapy in Post-Myocardial Infarction Patients with Acute Ischemic Stroke with and without Atrial Fibrillation. JCM 2022;11:3894. [DOI: 10.3390/jcm11133894] [Reference Citation Analysis]
149 Moustafa A, Khan MS, Marei A, Alsamman MA, Baig M, Saad M. Safety and efficacy of dual versus triple antithrombotic therapy in Patients with atrial fibrillation undergoing percutaneous coronary intervention: A meta-analysis. Avicenna J Med 2020;10:232-40. [PMID: 33437696 DOI: 10.4103/ajm.ajm_40_20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
150 Yashima F, Inohara T, Nishida H, Shimoji K, Ueno K, Noma S, Yamaji K, Ishii H, Tanaka N, Kohsaka S, Amano T, Ikari Y. In-hospital Bleeding Outcomes of Oral Anticoagulant and Dual Antiplatelet Therapy During Percutaneous Coronary Intervention: An Analysis From the Japanese Nationwide Registry. J Cardiovasc Pharmacol 2021;78:221-7. [PMID: 34554675 DOI: 10.1097/FJC.0000000000001006] [Reference Citation Analysis]
151 Fanaroff AC, Lopes RD. The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Prog Cardiovasc Dis 2021:S0033-0620(21)00129-8. [PMID: 34883097 DOI: 10.1016/j.pcad.2021.11.010] [Reference Citation Analysis]
152 Lüscher TF, Davies A, Beer JH, Valgimigli M, Nienaber CA, Camm JA, Baumgartner I, Diener HC, Konstantinides SV. Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. Eur Heart J 2021:ehab642. [PMID: 34624084 DOI: 10.1093/eurheartj/ehab642] [Reference Citation Analysis]
153 Dawwas GK, Barnes GD, Dietrich E, Cuker A, Leonard CE, Genuardi MV, Lewis JD. Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis. Am Heart J 2021;242:71-81. [PMID: 34450051 DOI: 10.1016/j.ahj.2021.08.014] [Reference Citation Analysis]
154 Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A. Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. Pharmaceutics 2022;14:1120. [DOI: 10.3390/pharmaceutics14061120] [Reference Citation Analysis]
155 Eccleston DS, Kim JM, Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, de Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Cannon CP. The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials). Clin Cardiol 2021;44:1002-10. [PMID: 34042199 DOI: 10.1002/clc.23649] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
156 Lasica R, Djukanovic L, Popovic D, Savic L, Mrdovic I, Radovanovic N, Radovanovic MR, Polovina M, Stojanovic R, Matic D, Uscumlic A, Asanin M. Use of Anticoagulant Therapy in Patients with Acute Myocardial Infarction and Atrial Fibrillation. Medicina 2022;58:338. [DOI: 10.3390/medicina58030338] [Reference Citation Analysis]
157 Goette A. Antithrombotic therapy after coronary artery stenting in atrial fibrillation: dual therapy encompassing NOAC plus P2Y12 inhibitor is ready for prime time! Ann Transl Med 2019;7:S270. [PMID: 32015989 DOI: 10.21037/atm.2019.12.33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
158 Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Shimono Y, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Yuri Y, Nishimura T, Iijima H, Nishiguchi S. Serum Zinc Level Grading System: A Useful Model for Composite Hepatic Events in Hepatitis C Virus-Associated Liver Cirrhosis. J Clin Med 2020;9:E643. [PMID: 32121095 DOI: 10.3390/jcm9030643] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
159 Eberhardt TE, Bungard TJ, Graham MM, Picard M, Wang GT, Ackman ML. Effect of New Evidence on Antithrombotic Therapies in Atrial Fibrillation Patients Who Undergo Percutaneous Coronary Intervention in Alberta, Canada. CJC Open 2021. [DOI: 10.1016/j.cjco.2021.12.007] [Reference Citation Analysis]
160 Capodanno D, Bhatt DL, Eikelboom JW, Fox KAA, Geisler T, Michael Gibson C, Gonzalez-Juanatey JR, James S, Lopes RD, Mehran R, Montalescot G, Patel M, Steg PG, Storey RF, Vranckx P, Weitz JI, Welsh R, Zeymer U, Angiolillo DJ. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol 2020;17:242-57. [PMID: 31953535 DOI: 10.1038/s41569-019-0314-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 18.5] [Reference Citation Analysis]
161 Ono K, Iwasaki Y, Akao M, Ikeda T, Ishii K, Inden Y, Kusano K, Kobayashi Y, Koretsune Y, Sasano T, Sumitomo N, Takahashi N, Niwano S, Hagiwara N, Hisatome I, Furukawa T, Honjo H, Maruyama T, Murakawa Y, Yasaka M, Watanabe E, Aiba T, Amino M, Itoh H, Ogawa H, Okumura Y, Aoki-kamiya C, Kishihara J, Kodani E, Komatsu T, Sakamoto Y, Satomi K, Shiga T, Shinohara T, Suzuki A, Suzuki S, Sekiguchi Y, Nagase S, Hayami N, Harada M, Fujino T, Makiyama T, Maruyama M, Miake J, Muraji S, Murata H, Morita N, Yokoshiki H, Yoshioka K, Yodogawa K, Inoue H, Okumura K, Kimura T, Tsutsui H, Shimizu W; on behalf of the Japanese Circulation Society and Japanese Heart Rhythm Society Joint Working Group. JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Circ J. [DOI: 10.1253/circj.cj-20-1212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
162 Iida H, Miyake T, Tani M, Tanaka T, Kawakami K, Ikuno Y, Mandai R, Shimizu T. Cerebellar hemorrhage in patients treated with edoxaban for portal vein thrombosis after hepatobiliary surgery: a report of two cases. Surg Case Rep 2020;6:319. [PMID: 33305345 DOI: 10.1186/s40792-020-01086-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
163 Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C, Wojakowski W; ESC/EACTS Scientific Document Group., ESC Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2021:ehab395. [PMID: 34453165 DOI: 10.1093/eurheartj/ehab395] [Cited by in Crossref: 39] [Article Influence: 39.0] [Reference Citation Analysis]
164 Welsh RC, Dehghani P, Lopes R, Wojdyla DM, Aronson R, Granger CB, Windecker S, Vora AN, Vinereanu D, Halvorsen S, Parkhomenko A, Mehran R, Alexander JH, Goodman S. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart 2022;9:e001892. [PMID: 35172988 DOI: 10.1136/openhrt-2021-001892] [Reference Citation Analysis]
165 Camaj A, Miller MS, Halperin JL, Giustino G. Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Cardiol Clin 2020;38:551-61. [PMID: 33036717 DOI: 10.1016/j.ccl.2020.07.006] [Reference Citation Analysis]
166 Fernando H, Mcfadyen JD, Wang X, Shaw J, Stub D, Peter K. P2Y12 Antagonists in Cardiovascular Disease—Finding the Best Balance Between Preventing Ischemic Events and Causing Bleeding. Front Cardiovasc Med 2022;9:854813. [DOI: 10.3389/fcvm.2022.854813] [Reference Citation Analysis]
167 Chong DT, Andreotti F, Verhamme P, Dalal J, Uaprasert N, Wang CC, On YK, Li YH, Jiang J, Hasegawa K, Almuti K, Bai R, Lo ST, Krittayaphong R, Lee LH, Quek DK, Johar S, Seow SC, Hammett CJ, Tan JW. Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management. Eur Cardiol 2021;16:e23. [PMID: 34135993 DOI: 10.15420/ecr.2020.43] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
168 Brunetti ND, Tricarico L, De Gennaro L, Correale M, Santoro F, Ieva R, Iacoviello M, Di Biase M. Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? Int J Cardiol Heart Vasc 2020;29:100569. [PMID: 32637570 DOI: 10.1016/j.ijcha.2020.100569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
169 de Veer AJWM, Bennaghmouch N, Dewilde WJM, Ten Berg JM. How cardiologists manage antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary stenting: the WOEST survey 2018. Neth Heart J 2021;29:135-41. [PMID: 33052578 DOI: 10.1007/s12471-020-01500-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
170 Bor W, Gorog DA. Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. J Clin Med 2020;9:E2020. [PMID: 32605128 DOI: 10.3390/jcm9072020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
171 Gao F, Rahman F. DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm. Curr Atheroscler Rep 2022. [PMID: 35386093 DOI: 10.1007/s11883-022-01022-w] [Reference Citation Analysis]
172 Baumbach A, Bourantas CV, Serruys PW, Wijns W. The year in cardiology: coronary interventions. Eur Heart J 2020;41:394-405. [PMID: 31901934 DOI: 10.1093/eurheartj/ehz947] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
173 Eyileten C, Postula M, Jakubik D, Toma A, Mirowska-Guzel D, Patti G, Renda G, Siller-Matula JM. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. J Clin Med 2020;9:E1120. [PMID: 32295160 DOI: 10.3390/jcm9041120] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
174 Genz C, Braun-Dullaeus RC. Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation. Dtsch Arztebl Int 2021;118:arztebl. [PMID: 33637173 DOI: 10.3238/arztebl.m2021.0150] [Reference Citation Analysis]
175 Fanaroff AC, Li S, Marquis-Gravel G, Giri J, Lopes RD, Piccini JP, Wang TY. Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy. Circ Cardiovasc Interv 2021;14:e011232. [PMID: 34932388 DOI: 10.1161/CIRCINTERVENTIONS.121.011232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Schäfer A, Flierl U, Bauersachs J. Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI. Clin Res Cardiol 2021;110:759-74. [PMID: 32696081 DOI: 10.1007/s00392-020-01708-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
177 Alexopoulos D. In the search of the 'sweet spot' for aspirin discontinuation time in AF patients post PCI. Int J Cardiol 2022:S0167-5273(22)00646-5. [PMID: 35523372 DOI: 10.1016/j.ijcard.2022.04.082] [Reference Citation Analysis]
178 Zeymer U, Toelg R, Wienbergen H, Hobbach HP, Cuneo A, Bekeredjian R, Ritter O, Hailer B, Hertting K, Hennersdorf M, Scholtz W, Lanzer P, Mudra H, Schwefer M, Schwimmbeck PL, Liebetrau C, Thiele H, Claas C, Riemer T, Zahn R. Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany. Herz 2022. [PMID: 35243515 DOI: 10.1007/s00059-022-05099-6] [Reference Citation Analysis]